Anticonvulsants are a broad class of drugs used to treat epileptic seizures. Since many anticonvulsants tend to operate as mood stabilizers, they are also being used more frequently to treat neuropathic pain, bipolar disorder, and borderline personality disorder. Anticonvulsants, including gabapentin, carbamazepine, and valproic acid, are believed to alleviate chronic pain by obstructing sodium (valproate and the gabapentanoids) or calcium (carbamazepine and Oxcarbazepine) channels at the cellular neuronal level. This suppresses spontaneous electrical activity and restores the normal threshold to depolarization of hypersensitive nociceptive neurons without affecting normal nerve conduction.
Patients with neuropathic pain and mood disorders benefit most from these drugs. Anticonvulsant drugs are classified as either first-generation (classic) agents or second-generation agents. Second-generation anticonvulsants are usually better tolerated and have a broader therapeutic range than classic anticonvulsant drugs. The choice of drug is guided by the type of seizure. First-line treatment for focal seizures includes lamotrigine or levetiracetam, while valproate is used for generalized seizures. While all anticonvulsants have dose-dependent side effects on the central nervous system (e.g., somnolence, nausea), select agents also have other side effects (e.g., gingival hyperplasia caused by phenytoin).
Market Dynamics
Increasing prevalence of epilepsy is expected to propel the market growth over the forecast period. For instance, according to the World Health Organization, in February 2022, epilepsy is one of the most common neurological diseases globally, which affects around 50 million people. Nearly 80% of people with epilepsy live in low- and middle-income countries. According to the same source, it is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated.
Key features of the study:
- This report provides an in-depth analysis of the global anticonvulsant drugs market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anticonvulsant drugs market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
- Key companies covered as a part of this study include Novartis AG, GSK plc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy’s Laboratories Ltd., Alkem Labs, SK BIOPHARMACEUTICALS, Eisai Co., Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and Bausch Health Companies Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global anticonvulsant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticonvulsant drugs market
Detailed Segmentation:
- Global Anticonvulsant Drugs Market, By Drug Class:
- Barbiturates
- Benzodiazepines
- Aromatic allylic alcohols
- Carboxamides
- Triazine
- AMPA receptor antagonists
- Carbamate
- Hydantoin
- Fatty Acid Derivative
- GABA analogs
- Valproylamides
- Others (Propionates, Oxazolidinediones, etc.)
- Global Anticonvulsant Drugs Market, By Route of Administration:
- Global Anticonvulsant Drugs Market, By Indication:
- Epilepsy
- Neuropathic pain
- Anxiety
- Fibromyalgia
- Bipolar Disorder
- Others (Borderline personality disorder, etc.)
- Global Anticonvulsant Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Anticonvulsant Drugs Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Novartis AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GSK plc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy’s Laboratories Ltd.
- Alkem Labs
- SK BIOPHARMACEUTICALS
- Eisai Co., Ltd
- Angelini S.p.a.
- Sun Pharmaceutical Industries Ltd.
- UCB S.A.
- Unichem Laboratories
- Jazz Pharmaceuticals, Inc.
- Neuropathix, Inc.
- Xenon Pharmaceuticals, Inc.
- SK Life Science, Inc.
- Sumitomo Pharma Co., Ltd
- Bausch Health Companies Inc.
“*” marked represents similar segmentation in other categories in the respective section.
